SABCS 2022 | DESTINY-Breast07: T-DXd+/- pertuzumab in patients with metastatic HER2+ breast cancer

Erika Hamilton, MD, Sarah Cannon Cancer Center, Nashville, TN, provides an overview of the preliminary data of the Phase Ib/II DESTINY-Breast07 (NCT04538742) dose-expansion study of trastuzumab deruxtecan (T-DXd) as monotherapy or combined with pertuzumab in patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer. The combination of T-DXd with pertuzumab demonstrated a manageable safety profile, although an increase in diarrhea was observed due to the addition of pertuzumab. The response rate between T-DXd as a monotherapy versus in combination with pertuzumab was not significantly different. However, the data for progression-free survival (PFS) is immature, as over ¾ of patients are still on ongoing treatment. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.